Endophenotyping With Functional Magnetic Resonance Imaging (fMRI)

NCT01503931 | Completed DMC

• 1 other identifier: 01GS08159
• Study Type: observational
• Target: 480
• Locations: 1 country
• Sites: 1

Brief Summary

The mesolimbic dopaminergic reward system is a key structure underlying addictive behaviour in alcohol addiction and is under control of prefrontal glutamatergic neurotransmission. The aim of the present multicenter-study in Berlin, Bonn and Mannheim is to use functional magnetic resonance imaging (fMRI) in alcohol addiction for endophenotyping in order to study the relevance of genetic variation, in particular in dopaminergic and glutamatergic genes, for addiction. The investigators will use a temporal discounting and a cue reactivity paradigm in alcoholics and healthy controls in order to 1) test the impact of genetic variation on activation of the mesolimbic system in these populations and to 2) to test their predictive effects for treatment outcome in alcoholics. The subproject will thus bridge animal research on genetically determined cue reactivity and human studies in alcoholics. Furthermore, the investigators will link these results to the measurement of glutamate and glutamine with magnetic resonance spectroscopy (MRS) in subproject SP14.

Conditions

Alcohol Dependence

Keywords

alcohol dependence, functional magnetic resonance imaging, genetics, endophenotypes, dopamine,; glutamate

Outcome Measures

Primary Outcomes (2)

• blood oxygenation level dependent (BOLD) response

  investigation of neuronal activation of the mesolimbic system in alcohol-dependent patients and healthy controls using 3 tesla magnetic resonance imaging

  first assessment timepoint (alc.dep. patients: up to 21 days after detoxification)

• Genetic endophenotypes

  study the relevance of genetic variation, in particular in dopaminergic and glutamatergic genes, for addiction

  second assessment timepoint: 3 days after first assessment time point

Secondary Outcomes (1)

• Treatment response

  6 month follow up period beginning after second assessment timepoint

Study Arms (2)

Alcohol-dependent patients

* men and women, aged 18 to 75 * legally effective, written informed consent for participation within the study * right handedness * no other psychiatric disorder according to ICD 10 * no psychotropic substances within the last 7 days

Healthy control subjects

* men and women, aged 18 to 75 * legally effective, written informed consent for participation within the study * right handedness * no psychiatric disorder according to ICD 10 * no psychotropic substances within the last 7 days

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

primary care clinic

You may qualify if:

• Healthy Controls
• men and women, aged 18 to 75
• legally effective, written informed consent for participation within the study
• right handedness
• no psychiatric disorder according to ICD 10
• no psychotropic substances within the last 7 days Alcohol-dependent patients
• men and women, aged 18 to 75
• legally effective, written informed consent for participation within the study
• right handedness
• no other psychiatric disorder according to ICD 10
• no psychotropic substances within the last 7 days

You may not qualify if:

• physical disorders, which might interfere with the planned examination (e.g. cerebral or organic disorder)
• MR-contraindication (z.B. pace maker, metalic or electronic implants, metal splinters, operation clips)
• anamnestic manifest psychiatric axis I disorder and/or axis II according to ICD-10 except alcohol dependence for patients
• medication or drug dependence
• medication or drug abuse (randomized urin testing)
• insufficient knowledge of German language
• claustrophobia

Sponsors & Collaborators

• Charite University, Berlin, Germany: lead
• Central Institute of Mental Health, Mannheim: collaborator
• University Hospital, Bonn: collaborator

Study Sites (1)

Dept. of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, 10117, Germany

Location

Related Publications (1)

• Jorde A, Bach P, Witt SH, Becker K, Reinhard I, Vollstadt-Klein S, Kirsch M, Hermann D, Charlet K, Beck A, Wimmer L, Frank J, Treutlein J, Spanagel R, Mann K, Walter H, Heinz A, Rietschel M, Kiefer F. Genetic variation in the atrial natriuretic peptide transcription factor GATA4 modulates amygdala responsiveness in alcohol dependence. Biol Psychiatry. 2014 May 15;75(10):790-7. doi: 10.1016/j.biopsych.2013.10.020. Epub 2013 Nov 4.

  PMID: 24314346 DERIVED

Related Links

• Homepage of the project (NGFN PLUS TP 13)

Biospecimen

Retention: SAMPLES WITH DNA

whole blood (EDTA)

MeSH Terms

Conditions

Alcoholism

Condition Hierarchy (Ancestors)

Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Andreas Heinz, MD

  Charite University, Berlin, Germany

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr. med.

Study Record Dates

• First Submitted: January 2, 2012
• First Posted: January 4, 2012
• Study Start: June 1, 2008
• Primary Completion: February 1, 2013
• Study Completion: June 1, 2013
• Last Updated: January 28, 2016

Record last verified: 2016-01

Locations

DE (1)